Antisense oligonucleotides are single-stranded oligodeoxynucleotides that can alter the RNA and modify protein expression. These oligonucleotides were discovered to influence RNA processing. Subsequent chemical modifications of antisense oligonucleotides were used to address issues such as off-target toxic effects and insufficient biological activity. These modifications led to an improved mechanism of antisense oligonucleotides and clinical trial design. This paved the way toward translating their use into therapies for various genetic and neurological conditions. Antisense oligonucleotides mediated therapies target the source of pathogenesis and have higher chance of success as compared to therapies that target downstream pathways. These are drugs for the treatment of central nervous system (CNS) disorders, as they have specific molecular targeting and extended pharmacological properties.
This report contains market size and forecasts of CNS Specific Antisense Oligonucleotides in Global, including the following market information:
Global CNS Specific Antisense Oligonucleotides Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global CNS Specific Antisense Oligonucleotides market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Polyneuropathy Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of CNS Specific Antisense Oligonucleotides include Akcea Therapeutics, Inc., Ionis Pharmaceuticals Inc., Biogen Inc., Sarepta Therapeutics, Wave Life Sciences Ltd., Dynacure, ProQR Therapeutics N.V. and Stroke Therapeutic Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CNS Specific Antisense Oligonucleotides companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CNS Specific Antisense Oligonucleotides Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global CNS Specific Antisense Oligonucleotides Market Segment Percentages, by Type, 2021 (%)
Polyneuropathy Treatment
Spinal Muscular Atrophy (SMA) Treatment
Huntington’s Disease Treatment
Global CNS Specific Antisense Oligonucleotides Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global CNS Specific Antisense Oligonucleotides Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global CNS Specific Antisense Oligonucleotides Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global CNS Specific Antisense Oligonucleotides Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CNS Specific Antisense Oligonucleotides revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies CNS Specific Antisense Oligonucleotides revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Akcea Therapeutics, Inc.
Ionis Pharmaceuticals Inc.
Biogen Inc.
Sarepta Therapeutics
Wave Life Sciences Ltd.
Dynacure
ProQR Therapeutics N.V.
Stroke Therapeutic Inc.